Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.35 |
| ▸ | GHSR | Q92847 | 3/20 | 0.35 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179679 | 0.99 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4TLR7 | |
| SCHEMBL4186030 | 0.94 | ADORA2A (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4ADORA2B | |
| SCHEMBL4169858 | 0.94 | ADORA2A (0.37) | CHRNB2CHRNB4CHRNA3CHRNA4ADORA2B | |
| SCHEMBL4173736 | 0.94 | ADORA2B (0.37) | ADORA2BADORA2AITGB3ITGA2BMAPT | |
| SCHEMBL4165128 | 0.93 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4TLR7 | |
| SCHEMBL4180241 | 0.93 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4TLR7 | |
| SCHEMBL4173940 | 0.92 | MAPT (0.36) | ADORA2BADORA2AITGB3ITGA2BMAPT | |
| SCHEMBL4184656 | 0.91 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4ADORA2B | |
| SCHEMBL4174089 | 0.91 | CHRNB2 (0.38) | CHRNB2CHRNB4CHRNA3CHRNA4ADORA2B | |
| SCHEMBL4174562 | 0.90 | TLR7 (0.44) | TLR7ADORA2BADORA2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090068101-A9 | A1 Adenosine Receptor Antagonists | ENDACEA, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20070274910-A1 | e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | ENDACEA, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| EP-1636230-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | Endacea, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004110379-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070274910-A1 | e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | HRH3, HRH1, HRH2 | CHRNB2 237/4885CHRNB4 394/4885CHRNA3 121/4885 |
| US-20090068101-A9 | A1 Adenosine Receptor Antagonists | ADORA1, ADORA3, ADORA2A | CHRNB2 293/4885CHRNB4 306/4885CHRNA3 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.